CL2020001888A1 - Terapia de combinación para tratar o prevenir el cáncer. - Google Patents

Terapia de combinación para tratar o prevenir el cáncer.

Info

Publication number
CL2020001888A1
CL2020001888A1 CL2020001888A CL2020001888A CL2020001888A1 CL 2020001888 A1 CL2020001888 A1 CL 2020001888A1 CL 2020001888 A CL2020001888 A CL 2020001888A CL 2020001888 A CL2020001888 A CL 2020001888A CL 2020001888 A1 CL2020001888 A1 CL 2020001888A1
Authority
CL
Chile
Prior art keywords
combination therapy
treat
prevent cancer
cancer
prevent
Prior art date
Application number
CL2020001888A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808628.0A external-priority patent/GB201808628D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of CL2020001888A1 publication Critical patent/CL2020001888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención provee una terapia de combinación que comprende una cepa bacteriana para el tratamiento y la prevención del cáncer.
CL2020001888A 2018-01-19 2020-07-17 Terapia de combinación para tratar o prevenir el cáncer. CL2020001888A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808628.0A GB201808628D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
CL2020001888A1 true CL2020001888A1 (es) 2020-12-18

Family

ID=65228590

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001888A CL2020001888A1 (es) 2018-01-19 2020-07-17 Terapia de combinación para tratar o prevenir el cáncer.

Country Status (18)

Country Link
US (3) US20210060095A1 (es)
EP (1) EP3740218A1 (es)
JP (1) JP2021516216A (es)
KR (1) KR20200111183A (es)
CN (1) CN111629739A (es)
AU (1) AU2019210002A1 (es)
BR (1) BR112020014676A2 (es)
CA (1) CA3088413A1 (es)
CL (1) CL2020001888A1 (es)
CO (1) CO2020010013A2 (es)
IL (1) IL275949A (es)
MA (1) MA51613A (es)
MX (1) MX2020007671A (es)
NI (1) NI202000052A (es)
PH (1) PH12020551080A1 (es)
SG (1) SG11202006871YA (es)
TW (1) TW201938180A (es)
WO (1) WO2019141996A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023041574A1 (en) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2023041203A1 (en) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprising bacterial strains
CN115569193B (zh) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains
KR20240115991A (ko) * 2023-01-19 2024-07-29 재단법인 대구경북첨단의료산업진흥재단 골 질환 예방 또는 치료를 위한 신규 유산균 및 이의 배양액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
RU2017141448A (ru) * 2015-06-01 2019-07-15 Зэ Юниверсити Оф Чикаго Лечение рака путем манипуляций с комменсальной микрофлорой
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (zh) * 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物

Also Published As

Publication number Publication date
NI202000052A (es) 2021-01-20
AU2019210002A1 (en) 2020-08-13
CA3088413A1 (en) 2019-07-25
TW201938180A (zh) 2019-10-01
WO2019141996A1 (en) 2019-07-25
US20240016861A1 (en) 2024-01-18
EP3740218A1 (en) 2020-11-25
US20210060095A1 (en) 2021-03-04
CO2020010013A2 (es) 2020-08-31
MX2020007671A (es) 2020-09-14
IL275949A (en) 2020-08-31
CN111629739A (zh) 2020-09-04
US20230048366A1 (en) 2023-02-16
JP2021516216A (ja) 2021-07-01
KR20200111183A (ko) 2020-09-28
SG11202006871YA (en) 2020-08-28
PH12020551080A1 (en) 2021-08-02
MA51613A (fr) 2020-11-25
BR112020014676A2 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
CL2020001888A1 (es) Terapia de combinación para tratar o prevenir el cáncer.
CY1122867T1 (el) Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
PE20180268A1 (es) Composiciones que comprenden cepas bacterianas
MX2022008868A (es) Tratamiento del cancer con tg02.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
BR112017013982A2 (pt) fármaco de combinação
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
ES2980581T3 (es) Compuestos novedosos y su uso en terapia
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.